Drugs / RotaTeq™ Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00496054 | May → Oct 2008 | Rotavirus infection, gastroenteritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RotaTeq Vaccine | “RotaTeq™ Vaccine” NCT00496054 ↗ |
| Modality | Vaccine | “Three doses of oral pentavalent rotavirus vaccine (PRV) were administered with an interval of 4 to 10 weeks (28 to 70 days).” PMID 23442588 ↗ Jan 2013 |
| Route | Oral | “Three doses of oral pentavalent rotavirus vaccine (PRV) were administered with an interval of 4 to 10 weeks (28 to 70 days).” PMID 23442588 ↗ Jan 2013 |